Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Feb 1;40(4):335-344.
doi: 10.1200/JCO.21.01375. Epub 2021 Dec 6.

Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A

Affiliations
Clinical Trial

Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A

Wayne L Furman et al. J Clin Oncol. .

Abstract

Purpose: We evaluated whether combining a humanized antidisialoganglioside monoclonal antibody (hu14.18K322A) throughout therapy improves early response and outcomes in children with newly diagnosed high-risk neuroblastoma.

Patients and methods: We conducted a prospective, single-arm, three-stage, phase II clinical trial. Six cycles of induction chemotherapy were coadministered with hu14.18K322A, granulocyte-macrophage colony-stimulating factor (GM-CSF), and low-dose interleukin-2 (IL-2). The consolidation regimen included busulfan and melphalan. When available, an additional cycle of parent-derived natural killer cells with hu14.18K322A was administered during consolidation (n = 31). Radiation therapy was administered at the end of consolidation. Postconsolidation treatment included hu14.18K322A, GM-CSF, IL-2, and isotretinoin. Early response was assessed after the first two cycles of induction therapy. End-of-induction response, event-free survival (EFS), and overall survival (OS) were evaluated.

Results: Sixty-four patients received hu14.18K322A with induction chemotherapy. This regimen was well tolerated, with continuous infusion narcotics. Partial responses (PRs) or better after the first two chemoimmunotherapy cycles occurred in 42 of 63 evaluable patients (66.7%; 95% CI, 55.0 to 78.3). Primary tumor volume decreased by a median of 75% (range, 100% [complete disappearance]-5% growth). Median peak hu14.18K322A serum levels in cycle one correlated with early response to therapy (P = .0154, one-sided t-test). Sixty of 62 patients (97%) had an end-of-induction partial response or better. No patients experienced progressive disease during induction. The 3-year EFS was 73.7% (95% CI, 60.0 to 83.4), and the OS was 86.0% (95% CI, 73.8 to 92.8), respectively.

Conclusion: Adding hu14.18K322A to induction chemotherapy improved early objective responses, significantly reduced tumor volumes in most patients, improved end-of-induction response rates, and yielded an encouraging 3-year EFS. These results, if validated in a larger study, may be practice changing.

Trial registration: ClinicalTrials.gov NCT01857934.

PubMed Disclaimer

Conflict of interest statement

Barry L. ShulkinConsulting or Advisory Role: Navidea Matthew KrasinConsulting or Advisory Role: Debiopharm Group Michael W. BishopConsulting or Advisory Role: Fennec PharmaResearch Funding: Pfizer Fariba NavidResearch Funding: Bayer (Inst) Brandon TriplettTravel, Accommodations, Expenses: Miltenyi Biotec Stephen D. GilliesEmployment: LinkedUp BioscienceLeadership: LinkedUp BioscienceStock and Other Ownership Interests: Provenance BiopharmaceuticalsConsulting or Advisory Role: Delos Capital PartnersPatents, Royalties, Other Intellectual Property: Patent owner not related to this paper Alice YuLeadership: OPKO HealthStock and Other Ownership Interests: OPKO Health/GeneDxHonoraria: EUSA PharmaConsulting or Advisory Role: OBI PharmaSpeakers' Bureau: EUSA PharmaResearch Funding: United Therapeutics (Inst)Patents, Royalties, Other Intellectual Property: Globo H-Diphtheria toxoid vaccine for cancer therapy, NKT stimulatory phenyl-glycolipids for cancer therapy and vaccine adjuvant, Cancer targeting peptides, Methods for suppressing cancer by inhibition of TMCC3Travel, Accommodations, Expenses: EUSA Pharma Paul M. SondelResearch Funding: Invenra Inc (Inst)Patents, Royalties, Other Intellectual Property: I have partial interest in patents related to my work at the University of Wisconsin-Madison WI, which are held by and managed by the University of Wisconsin Foundation. I am an unpaid medical advisor to Invenra Inc, a monoclonal antibody biotech firm in Madison WI. My UW laboratory is collaborating with Invenra and receiving research reagents from them for mutual researchUncompensated Relationships: Invenra Wing H. LeungEmployment: Miltenyi Biotec Alberto PappoHonoraria: Bayer, RocheConsulting or Advisory Role: Merck, Loxo/Bayer, EUSA Pharma, DebbioNo other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Study schema. BuMel, busulfan and melphalan; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-2, interleukin-2; NK, natural killer; PBSC, peripheral blood stem cell; XRT, radiation therapy.
FIG 2.
FIG 2.
Disease response assessed by INRC for patients (A) after induction cycle 2 and (B) at the end of induction. Each bar represents an individual patient. The primary tumor response is demonstrated as a percentile change in volume of the primary tumor compared with the primary tumor volume at baseline. The color of the individual bars signifies the metastatic response including anatomic imaging, functional imaging (MIBG or PET), and bone marrow assessment. The blue bar represents a complete metastatic response. The red bar represents a metastatic VGPR. The teal bar represents a metastatic partial response. The orange bar represents no metastatic response. The purple bar signifies patients without metastatic disease at diagnosis. Bone marrow response is depicted by the following shapes: gray triangle represents the presence of bone marrow disease at the time of the assessment, blue oval represents bone marrow disease present at baseline that resolved at the time of the assessment, and the red star represents no bone marrow disease at baseline. Together, the primary tumor response, metastatic response, and bone marrow response are used to inform the INRC overall response. The overall response of the individual patient is presented by the letter below each bar. The letter C signifies a CR; V is a VGPR; P is a PR; N is a no response; and E means that the patient was not evaluable at that time point because of the primary tumor resection performed before therapy. X represents a stage IV patient who did not have a primary tumor at diagnosis. O represents two patients who discontinued protocol therapy before completing induction. CR, complete response; INRC, International Neuroblastoma Response Criteria; MIBG, [125I]metaiodobenzylguanidine; PET, positron emission tomography; PR, partial response; VGPR, very good partial response.
FIG 3.
FIG 3.
Association of hu14.18K322A peak serum levels (µg/mL) and response after two cycles of chemoimmunotherapy. Relationship between response (CR or PR [n = 42] v SD or PD [n = 17]) and peak hu14.18K322A levels, measured on first day of mAb infusion, 1 hour after a 4-hour infusion. P = .0154 (one-tailed t-test). CR, complete response; mAb, monoclonal antibody; PD, progressive disease; PR, partial response; SD, stable disease.
FIG 4.
FIG 4.
Flow diagram. ASCT, autologous hematopoietic stem-cell transplant; mAb, monoclonal antibody; MRD, minimal residual disease; PD, progressive disease.
FIG 5.
FIG 5.
EFS and OS for all patients enrolled. EFS, event-free survival; OS, overall survival.

References

    1. Yu AL, Gilman AL, Ozkaynak MF, et al. : Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324-1334, 2010 - PMC - PubMed
    1. Yu AL, Gilman AL, Ozkaynak MF, et al. : Long-term follow-up of a phase III study of ch14.18 (dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032. Clin Cancer Res 27:2179-2189, 2021 - PMC - PubMed
    1. Nowak AK, Robinson BW, Lake RA: Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63:4490-4496, 2003 - PubMed
    1. Lake RA, Robinson BW: Immunotherapy and chemotherapy—A practical partnership. Nat Rev Cancer 5:397-405, 2005 - PubMed
    1. Hiddemann W, Kneba M, Dreyling M, et al. : Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 - PubMed

Publication types

MeSH terms

Substances

Associated data